HC Wainwright Reaffirms “Neutral” Rating for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports.

Separately, Robert W. Baird dropped their price target on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.75.

Agenus Price Performance

Shares of AGEN opened at $1.73 on Tuesday. The firm has a fifty day moving average price of $3.07 and a 200 day moving average price of $3.71. Agenus has a 1-year low of $1.64 and a 1-year high of $19.69. The stock has a market cap of $40.58 million, a PE ratio of -0.15 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last announced its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The business had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million. As a group, equities analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. FMR LLC lifted its holdings in shares of Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 27,309 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Agenus by 2,271.5% in the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Agenus in the third quarter valued at about $1,003,000. HighTower Advisors LLC lifted its holdings in shares of Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 7,530 shares in the last quarter. Finally, Point72 DIFC Ltd lifted its holdings in shares of Agenus by 380.0% in the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 11,542 shares in the last quarter. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.